Biologic Excipient Market

Biologic Excipient Market Size, Market Forecast and Outlook By FMI

The biologic excipient market was valued at USD 1.6 billion in 2025. The market is set to reach USD 1.6 billion by 2026-end and grow at a CAGR of 4.1% between 2026-2036 to reach USD 2.4 billion by 2036. Polymers will dominate with a 30.1% share, while Biopharmaceutical Manufacturers will lead with a 65.7% share.

Summary of the Biologic Excipient Market

• Demand and Growth Drivers
  • Biologic pipeline growth and formulation complexity are likely to support demand through the forecast period.
  • Regulatory quality standards and biosimilar development are expected to remain consistent growth drivers from 2026 to 2036.
  • Supply chain reliability requirements and new polymer development are expected to create additional opportunities.
• Product and Segment View
  • Polymers is likely to remain the leading excipient type segment, accounting for 30.1% of demand in 2026.
  • Biopharmaceutical Manufacturers is expected to account for 65.7% of the end user category.
  • Growth across segments is expected to remain uneven, with higher-specification categories outpacing standard alternatives.
• Geography and Competitive Outlook
  • Germany is likely to lead growth at 4.5% CAGR.
  • UK at 4% CAGR represents the second-fastest growth corridor.
  • Companies that combine product breadth with distribution reach and service capability are likely to strengthen competitive positioning.
• Analyst Opinion
  • The biologic excipient market is evolving toward higher-specification polymer excipients driven by formulation complexity and regulatory requirements. Companies that invest in quality systems, polymer development, and supply chain reliability are better positioned. The market is expected to create USD 0.80 billion in incremental opportunity between 2026 and 2036.
  • Growth is concentrated in regions where biopharmaceutical manufacturing is concentrated.
  • Adoption is increasing due to expanding biologic drug development pipelines, increasing complexity of biologic formulations, and growing demand for stability-enhancing excipients.
  • The strongest growth is expected from Germany and UK.

Key Takeaways, Market Size, and Forecast

• The biologic excipient market was valued at USD 1.56 billion in 2025.
• By 2036, the Biologic Excipient Market is expected to be worth USD 2.43 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 4.1%.
• The market is projected to create an incremental opportunity of USD 0.80 billion between 2026 and 2036.
• In 2026, Polymers is expected to account for 30.1% of the excipient type, driven by expanding biologic drug development pipelines, increasing complexity of biologic formulations, and growing demand for stability-enhancing excipients.
• Germany (4.5%) and UK (4%) are two of the fastest growing markets in the world.

Biologic Excipient Market Definition

The biologic excipient market encompasses all commercially traded products, solutions, and services categorized by excipient type, end user. Revenue from sales across North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa during 2026 to 2036.

Biologic Excipient Market Inclusions

Market scope includes all biologic excipient products sold commercially, covering Polymers, Sugar Alcohols, Polysorbates, Inorganic Salts, Amino Acids, Surfactants, Others; Biopharmaceutical Manufacturers, Contract Research Organizations, Contract Manufacturing Organizations, Research Organizations. Revenue tracked from 2026 to 2036.

Biologic Excipient Market Exclusions

The scope excludes non-commercial transactions, internal transfers, and prototype products. Government-funded research without commercial procurement is also excluded.

Biologic Excipient Market Research Methodology

• Primary Research: Interviews with manufacturers, distributors, and end-user procurement teams across key markets.
• Desk Research: Analysis of industry data, trade statistics, and regulatory filings.
• Market Sizing and Forecasting: Bottom-up aggregation of biopharmaceutical production data, excipient consumption volumes, and formulation development tracking, with regional curves and top-down validation.
• Data Validation: Cross-checked quarterly against production statistics and manufacturer disclosures.

Why is the Biologic Excipient Market Growing?

• Expanding biologic drug development pipelines, increasing complexity of biologic formulations, and growing demand for stability-enhancing excipients are supporting a CAGR of 4.1% through 2036.
• Germany leads growth at 4.5%.
• Polymers accounts for 30.1% of the excipient type segment.

The expanding pipeline of biologic drugs under development is the primary demand driver for specialized excipients. Each biologic formulation requires specific excipient combinations for stability, solubility, and delivery. The growing number of biologic drug approvals translates directly to increased excipient consumption in commercial manufacturing. Pipeline growth across monoclonal antibodies, biosimilars, and advanced therapy products creates sustained demand expansion.

The increasing complexity of biologic formulations is increasing the excipient content per product. Advanced delivery systems, high-concentration formulations, and combination products require more sophisticated excipient combinations. This complexity trend increases both the volume and value of excipient consumption per biologic drug product. Companies that offer technically differentiated excipient solutions capture premium positioning in formulation development partnerships.

Regulatory requirements for excipient quality, traceability, and consistency are tightening across major pharmaceutical markets. Compliance with pharmacopeial standards, GMP manufacturing, and documentation requirements creates procurement barriers that favor qualified suppliers. Quality standards are becoming more stringent as regulators focus on the critical role of excipients in biologic product performance. Companies with established quality systems and regulatory track records maintain competitive advantages.

Market Segmentation Analysis

• The biologic excipient market is segmented by excipient type, end user.
• Polymers maintains the largest share at 30.1% in 2026.
• Biopharmaceutical Manufacturers accounts for 65.7% of the end user category.

Market structure is concentrated in the top segments.

Insights into the Polymers Segment

Polymers accounts for 30.1% of the excipient type segment in 2026. Demand reflects the versatility and functional importance of polymer excipients in biologic formulations. Growth is expected to remain consistent through the forecast period.

Insights into the Biopharmaceutical Manufacturers Segment

Biopharmaceutical Manufacturers accounts for 65.7% of the end user segment in 2026. Demand reflects the concentration of excipient procurement among biopharmaceutical manufacturers. Growth is expected to remain consistent through the forecast period.

Biologic Excipient Market Drivers, Restraints, and Opportunities

• Biologic pipeline growth and quality requirements are creating structured demand.
• Raw material costs and supply chain complexity remain the primary restraints.
• Novel polymer development and biosimilar growth represent the most significant opportunities.

The biologic excipient market continues to expand as expanding biologic drug development pipelines, increasing complexity of biologic formulations, and growing demand for stability-enhancing excipients create sustained demand.

Biologic Pipeline Growth Drives Excipient Demand

The expanding pipeline of biologic drugs under development is the primary demand driver for specialized excipients. Each biologic formulation requires specific excipient combinations for stability, solubility, and delivery. The growing number of biologic drug approvals translates directly to increased excipient consumption in commercial manufacturing. Pipeline growth across monoclonal antibodies, biosimilars, and advanced therapy products creates sustained demand expansion.

Formulation Complexity Increases Excipient Content

The increasing complexity of biologic formulations is increasing the excipient content per product. Advanced delivery systems, high-concentration formulations, and combination products require more sophisticated excipient combinations. This complexity trend increases both the volume and value of excipient consumption per biologic drug product. Companies that offer technically differentiated excipient solutions capture premium positioning in formulation development partnerships.

Regulatory Quality Standards Raise Procurement Barriers

Regulatory requirements for excipient quality, traceability, and consistency are tightening across major pharmaceutical markets. Compliance with pharmacopeial standards, GMP manufacturing, and documentation requirements creates procurement barriers that favor qualified suppliers. Quality standards are becoming more stringent as regulators focus on the critical role of excipients in biologic product performance. Companies with established quality systems and regulatory track records maintain competitive advantages.

Polymer Excipients Maintain Dominant Position

Polymer-based excipients maintain the largest market share due to their versatility in controlling drug release, improving stability, and enabling targeted delivery. Polymer excipients serve multiple functions in biologic formulations, making them essential components. The technical depth of polymer excipient applications creates customer stickiness and switching costs. Manufacturers with comprehensive polymer portfolios and application expertise capture broader formulation opportunities.

Analysis of Biologic Excipient Market By Key Countries

Country	CAGR
Germany	4.5%
UK	4%
India	3.9%
USA	3.7%
China	3.4%

• Germany leads at 4.5% CAGR.
• UK at 4% represents the second-fastest growth corridor.
• India (3.9%) and USA (3.7%) show sustained growth.

The global biologic excipient market is expected to expand at a CAGR of 4.1% from 2026 to 2036.

Demand Outlook for Biologic Excipient Market in Germany

Germany is projected to register a CAGR of 4.5% through 2036. Growth reflects expanding biologic drug development, increasing formulation complexity, and growing regulatory emphasis on excipient quality and traceability.

• Biologic drug pipeline growth is increasing demand for specialized formulation ingredients.
• Regulatory quality requirements are driving specification upgrades in excipient procurement.
• Formulation complexity in biosimilars and next-generation biologics is expanding excipient consumption.

Future Outlook for Biologic Excipient Market in UK

UK is projected to register a CAGR of 4% through 2036. Growth reflects expanding biologic drug development, increasing formulation complexity, and growing regulatory emphasis on excipient quality and traceability.

• Biologic drug pipeline growth is increasing demand for specialized formulation ingredients.
• Regulatory quality requirements are driving specification upgrades in excipient procurement.
• Formulation complexity in biosimilars and next-generation biologics is expanding excipient consumption.

Opportunity Analysis of Biologic Excipient Market in India

India is projected to register a CAGR of 3.9% through 2036. Growth reflects expanding biologic drug development, increasing formulation complexity, and growing regulatory emphasis on excipient quality and traceability.

• Biologic drug pipeline growth is increasing demand for specialized formulation ingredients.
• Regulatory quality requirements are driving specification upgrades in excipient procurement.
• Formulation complexity in biosimilars and next-generation biologics is expanding excipient consumption.

In-depth Analysis of Biologic Excipient Market in USA

USA is projected to register a CAGR of 3.7% through 2036. Growth reflects expanding biologic drug development, increasing formulation complexity, and growing regulatory emphasis on excipient quality and traceability.

• Biologic drug pipeline growth is increasing demand for specialized formulation ingredients.
• Regulatory quality requirements are driving specification upgrades in excipient procurement.
• Formulation complexity in biosimilars and next-generation biologics is expanding excipient consumption.

Sales Analysis of Biologic Excipient Market in China

China is projected to register a CAGR of 3.4% through 2036. Growth reflects expanding biologic drug development, increasing formulation complexity, and growing regulatory emphasis on excipient quality and traceability.

• Biologic drug pipeline growth is increasing demand for specialized formulation ingredients.
• Regulatory quality requirements are driving specification upgrades in excipient procurement.
• Formulation complexity in biosimilars and next-generation biologics is expanding excipient consumption.

Competitive Landscape and Strategic Positioning

• FMC Corporation maintains a strong position.
• Wacker Chemie AG and Evonik Industries AG compete through specialized capabilities.
• New entrants target underserved segments and emerging markets.

The competitive landscape reflects a mix of global and regional players.

FMC Corporation leads through established infrastructure and multi-regional capabilities.

Barriers include capital requirements, certifications, and established customer relationships.

Key Companies in the Biologic Excipient Market

Key global companies include:

• FMC Corporation, Wacker Chemie AG, Evonik Industries AG, Ashland Global Holdings Inc. maintain strong positions.
• Archer-Daniels-Midland Co., Roquette Freres S.A., The Dow Chemical Company hold regional positions.
• Colorcon Inc., Signet Chemical Co. Pvt. Ltd., Sun Pharmaceutical Industries Ltd are emerging participants.

Competitive Benchmarking: Biologic Excipient Market

Company	Product Range	Quality Systems	Customer Access	Geographic Presence
FMC Corporation	High	High	Strong	Global
Wacker Chemie AG	High	High	Strong	Global
Evonik Industries AG	High	Medium	Strong	Global
Ashland Global Holdings Inc.	Medium	Medium	Moderate	Global
Archer-Daniels-Midland Co.	Medium	Medium	Moderate	Regional
Roquette Freres S.A.	Medium	Low	Moderate	Regional
The Dow Chemical Company	Low	Low	Moderate	Regional
Colorcon Inc.	Low	Low	Limited	Niche
Signet Chemical Co. Pvt. Ltd.	Low	Low	Limited	Niche
Sun Pharmaceutical Industries Ltd	Low	Low	Limited	Niche

Source: Future Market Insights competitive analysis, 2026

Key Players in the Biologic Excipient Market

Major Global Players

• FMC Corporation
• Wacker Chemie AG
• Evonik Industries AG
• Ashland Global Holdings Inc.
• Archer-Daniels-Midland Co.
• Roquette Freres S.A.
• The Dow Chemical Company

Emerging Players/Startups

• Colorcon Inc.
• Signet Chemical Co. Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 1.63 Billion to USD 2.43 Billion, at a CAGR of 4.1%
Market Definition	The biologic excipient market encompasses products and services across excipient type, end user.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	Germany, UK, India, USA, China, 30 plus countries
Key Companies Profiled	FMC Corporation, Wacker Chemie AG, Evonik Industries AG, Ashland Global Holdings Inc., Archer-Daniels-Midland Co., Roquette Freres S.A., The Dow Chemical Company, Colorcon Inc., Signet Chemical Co. Pvt. Ltd., Sun Pharmaceutical Industries Ltd
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data.

Segmentation

Biologic Excipient Market Segmented by Excipient Type:

• Polymers
• Sugar Alcohols
• Polysorbates
• Inorganic Salts
• Amino Acids
• Surfactants
• Others

Biologic Excipient Market Segmented by End User:

• Biopharmaceutical Manufacturers
• Contract Research Organizations
• Contract Manufacturing Organizations
• Research Organizations

Biologic Excipient Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• USA Food and Drug Administration. (2025). FDA Inactive Ingredient Database. FDA.
• European Medicines Agency. (2025). EMA Excipient Guidelines. EMA.
• Organisation for Economic Co-operation and Development. (2025). OECD Pharmaceutical Statistics. OECD.
• World Health Organization. (2025). WHO Pharmaceutical Quality Guidelines. WHO.
• International Pharmaceutical Excipients Council. (2025). IPEC Excipient Standards. IPEC.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list.

This Report Answers

• Estimating the size of the biologic excipient market and revenue potential from 2026 to 2036.
• Segmentation by excipient type, end user.
• Regional insights across more than 30 markets.
• Competitive landscape assessment and company benchmarking.
• Identification of investment opportunities across product segments and geographic markets.
• Supply chain and distribution channel tracking.
• Delivery of data in PDF and Excel formats.